Abstract. CXC ligand (L)12 is a chemokine implicated in the migration, invasion and metastasis of cancer cells via interaction with its receptors CXC chemokine receptor (CXCR)4 and CXCR7. In the present study, CXCL12-mediated Ca\^{2+} signalling was compared with two basal-like breast cancer cell lines, MDA-MB-231 and MDA-MB-468, which demonstrate distinct metastatic potential. CXCL12 treatment induced Ca\^{2+} responses in the more metastatic MDA-MB-231 cells but not in the less metastatic MDA-MB-468 cells. Assessment of mRNA levels of CXCL12 receptors and their potential modulators in both cell lines revealed that CXCR4 and CXCR7 levels were increased in MDA-MB-231 cells compared with MDA-MB-468 cells. Cluster of differentiation (CD)24, the negative regulator of CXCL12 responses, demonstrated increased expression in MDA-MB-468 cells compared with MDA-MB-231 cells, and the two cell lines expressed comparable levels of hypoxia-inducible factor (HIF)2α, a CXCR4 regulator. Induction of epithelial-mesenchymal transition (EMT) by epidermal growth factor exhibited opposite effects on CXCR4 mRNA levels compared with hypoxia-induced EMT. Neither EMT inducer exhibited an effect on CXCR7 expression, however hypoxia increased HIF2α expression levels in MDA-MB-468 cells. Analysis of the gene expression profiles of breast tumours revealed that the highest expression levels of CXCR4 and CXCR7 were in the Claudin-Low molecular subtype, which is markedly associated with EMT features.

Introduction

Chemokines are a superfamily of small (~8-14 kDa) molecules that mediate numerous cellular functions by activating G protein-coupled receptors (1). Chemokines and their respective receptors are also associated with metastasis in different types of cancer, including osteosarcoma (2) and neuroblastoma (3), as well as prostate (4) and breast (5) cancer. The chemokine CXC ligand 12 (CXCL12; also known as stromal cell-derived factor-1) is implicated in numerous cellular processes that are important in aspects of tumour progression. It interacts with its cognate receptors CXC chemokine receptor (R) type 4 (1) and CXCR7 (6) to regulate cell trafficking and adhesion, tumour vascularisation, cell proliferation and survival (7,8). CXCL12 enhances the invasiveness and migratory properties of breast cancer cells, particularly when these cells also express CXCR4 (9). Indeed, CXCR4 expression is upregulated in primary breast tumours compared with normal mammary epithelial cells (5) indicating that it serves an important function in the progression and metastasis of breast cancer (10,11). CXCL12 responses are regulated by other factors beyond its receptors CXCR4 and CXCR7. Among these factors is cluster of differentiation (CD)24, a glycosylated cell surface protein that acts as a signal transducer in modulating responses to B cell activation (12). Schabath et al (13) demonstrated that MDA-MB-231 breast cancer cells with low CD24 expression exhibit augmented CXCL12/CXCR4-mediated cell migration.
and enhanced tumour growth compared with MDA-MB-231 cells that express high exogenous levels of CD24, suggesting that higher CD24 expression decreases CXCL12 responses in breast cancer cells. Hypoxia-inducible factor-2α (HIF2α) also regulates CXCR4 expression (14) and may therefore influence CXCL12 responsiveness.

Certain cells respond to CXCL12 activation by releasing Ca\(^{2+}\) from the endoplasmic reticulum internal Ca\(^{2+}\) store via G-protein coupled receptor, triggering phospholipase C activation and the generation of inositol trisphosphate and diacylglycerol (7). Ca\(^{2+}\) signalling is associated with processes that occur during metastasis, including cell migration and invasion (15,16), as well as the induction of an increasingly invasive phenotype by stimulating the epithelial-mesenchymal transition (EMT) (17). EMT is a process whereby epithelial cells undergo conversion to an increasingly mesenchymal (invasive) phenotype (18). However, the nexus between CXCL12, Ca\(^{2+}\) signalling, CXCL12 modulators and receptors and EMT has not yet been fully evaluated.

The nature of Ca\(^{2+}\) store release as a result of CXCL12/CXCR4 interaction may be tissue-dependent and vary between cell types (7). Changes in Ca\(^{2+}\) signalling and/or the expression of specific modulators of Ca\(^{2+}\) signalling are a feature of some subtypes of breast cancer and these changes often differ between different breast cancer subtypes. For example, the ratio of the calcium release-activated calcium channel protein (Orai1) calcium influx pathway activators stromal interaction molecule 1/2 is higher in the basal molecular breast cancer subtype than in other subtypes (19). It has been demonstrated that Orai3 regulates store-operated Ca\(^{2+}\) entry in oestrogen receptor-positive breast cancer cell lines such as MCF-7 but does not in oestrogen receptor-negative breast cancer cell lines such as MDA-MB-231 (20). Elevated transient receptor potential cation channel V6 levels are more common in types of breast cancer that are oestrogen receptor-negative (21). Oestrogen receptor-negative breast cancer, particularly those of the triple-negative subtype, exhibit a significant overlap with molecularly defined basal breast cancer (22).

Basal breast cancer cell lines possess gene signatures that allow them to be divided into basal A and basal B subtypes (23). In the present study, Ca\(^{2+}\) signalling induced by CXCL12 was compared between two triple-negative basal breast cancer cell lines, MDA-MB-468 (basal A) and MDA-MB-231 (basal B). mRNA levels of CXCL12 receptors and their response modulators in EMT and in breast cancer cell lines of different molecular subtypes were also characterised. The present study therefore aimed to assess the potential heterogeneity of responses to CXCL12 in the context of induced Ca\(^{2+}\) increases in basal breast cancer.

**Materials and methods**

**Cell culture.** The human basal-like triple-negative breast cancer cell lines MDA-MB-231 and MDA-MB-468 were obtained from the American Type Culture Collection (Manassas, VA, USA) and The Brisbane Breast Bank, University of Queensland Centre for Clinical Research, (Brisbane, Australia) respectively, and maintained in Dulbecco’s modified Eagle’s medium (DMEM; D6546; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) supplemented with 10% foetal bovine serum (FBS, Sigma-Aldrich; Merck KGaA), L-glutamine (4 mM; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), penicillin 100 U/ml and streptomycin 100 µg/ml (Invitrogen; Thermo Fisher Scientific, Inc.) in a humidified incubator at 37°C in an atmosphere containing 5% CO\(_2\). Cells were routinely screened for mycoplasma contamination using the MycoAlert Mycoplasma Detection kit (LT07-218; Lonza Group Ltd., Basel, Switzerland) and validated by short tandem repeat profiling using the StemElite ID Profiling kit (Promega Corporation, Madison, WI, USA).

**Intracellular Ca\(^{2+}\) measurement.** For Ca\(^{2+}\) measurements, MDA-MB-231 (7.5x10\(^4\) cells/well) or MDA-MB-468 (1.5 x10\(^4\) cells/well) were seeded in a 96-well CellBIND plate (Corning Life Sciences, Corning, NY, USA) in antibiotic-free DMEM containing L-glutamine (4 mM) and 10% FBS (MDA-MB-468 cells were seeded at a higher density due to their slower proliferation rate). At 24 h post-plating, the FBS concentration was decreased to 8%. At 72 h post-plating, Ca\(^{2+}\) assays were performed using a fluorescence imaging plate reader, FLIPR\(^{\text{®}}\)TETRA (Molecular Devices, LLC, Sunnyvale, CA, USA) and 4 µM Fluo-4 AM dye (Molecular Probes; Thermo Fisher Scientific, Inc.) in physiological salt solution, as previously described (24). Cells were excited at 470-495 nm and emission was assessed at 515-575 nm over an 800 sec period. Relative cytoplasmic (Cyt) Ca\(^{2+}\) \([\text{Ca}^{2+}]_{\text{cyt}}\) was determined in the presence of 300 and 100 ng/ml recombinant human CXCL12 (R&D Systems, Inc., Minneapolis, MN, USA) or 100 µM adenosine 5′-triphosphate (ATP; Sigma-Aldrich; Merck KGaA). Data were acquired using ScreenWorks\(^{\circledR}\) software (v2.0.0.27, Molecular Devices, LLC) and are presented as the response over baseline, which is a measure of relative \([\text{Ca}^{2+}]_{\text{cyt}}\).

**RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).** Total RNA was isolated using the RNeasy\(^{\circledR}\) Plus Mini kit (Qiagen GmbH, Hilden, Germany). RT reactions were performed using an Omniscript Reverse Transcription kit (Qiagen GmbH) with random primers and RNase inhibitor (Promega Corporation), according to the manufacturer's protocol. qPCR was conducted using Applied Biosystems TaqMan gene expression assays and TaqMan Universal PCR Master mix (Applied Biosystems; Thermo Fisher Scientific, Inc.). Assays included CD24 (Assay ID: Hs02379687_s1), CXCR4 (Assay ID: Hs00237052_m1), CXCR7 (Assay ID: Hs00664172_s1), HIF2α (Assay ID: Hs01026149_m1) and the endogenous control 18S ribosomal RNA (4319413E). All amplifications were performed using universal cycling conditions [20 sec at 95°C (holding stage), followed by 40 cycles of denaturation for 1 sec at 95°C and combined annealing and extension steps for 20 sec at 60°C] in a StepOnePlus\(^{TM}\) Real-Time PCR System Thermal Cycling Block (Applied Biosystems; Thermo Fisher Scientific, Inc.). Data were normalised to 18S ribosomal RNA and analysed using the comparative \(C_{\text{q}}\) method as previously described (25).

**Epidermal growth factor (EGF)-induced EMT.** For assessment of EGF-induced EMT, MDA-MB-468 cells were plated
at a density of $2 \times 10^4$ into a 96-well plate and serum-starved (0.5% FBS) for 24 h prior to treatment with 50 ng/ml EGF (Sigma-Aldrich; Merck KGaA), as previously described (26). Total RNA was isolated at 24 h post-EGF treatment and subjected to RT-qPCR following the aforementioned protocol to assess the changes in CXCR4, CXCR7, CD24 and HIF2α expression.

**Hypoxia-induced EMT.** For hypoxia-induced EMT, MDA-MB-468 cells were seeded at a density of $2 \times 10^4$ in a 96-well plate and serum-deprived (0.5% FBS) for 24 h. Cells were then exposed to hypoxic conditions (1% O₂) in a Sanyo MCO-18M multi-gas incubator (Sanyo Electric Co., Ltd., Tokyo, Japan). Normoxic control MDA-MB-468 cells were incubated in a humidified incubator (37°C, 5% CO₂) with normal atmosphere (21% O₂). Total RNA was isolated at 24 h following normoxic or hypoxic conditions to assess changes in CXCR4, CXCR7, CD24 and HIF2α expression, following the aforementioned protocol.

**Analysis of CXCR4 and CXCR7 expression in breast tumours.** Breast tumour gene expression data were sourced from the METABRIC breast cancer data (www.cbioportal.org, last accessed April 3, 2017) (27-29). This dataset comprises gene expression profiles from 1,860 tumours from six molecular subtypes including 198 basal-like (Basal), 182 Claudin-low (C-low), 218 human epidermal growth factor receptor 2-enriched (HER2), 673 luminal A (LumA), 454 luminal B (LumB) and 135 normal-like (N-Like).

**Statistical analysis.** Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA, USA). Results are expressed as the mean ± standard deviation from the specified number of independent experiments.
The statistical tests used are stated in each figure legend, and included one-way analysis of variance followed by Tukey's multiple comparison and an unpaired t-test, where appropriate.

**Results**

**CXCL12-induced intracellular free Ca\(^{2+}\) increases in breast cancer cells.** The effects of CXCL12 on intracellular Ca\(^{2+}\) concentrations were assessed in two basal-like breast cancer cell lines, MDA-MB-231 (basal B) and MDA-MB-468 (basal A). A significant concentration-dependent increase in \([\text{Ca}^{2+}]_{\text{CYT}}\) was observed following CXCL12 treatment in MDA-MB-231 breast cancer cells \((P<0.01; \text{Fig. 1A and B)}\) compared with the untreated control. However, no significant increase in \([\text{Ca}^{2+}]_{\text{CYT}}\) was observed in MDA-MB-468 cells treated with CXCL12 compared with the untreated control, despite a pronounced elevation in intracellular Ca\(^{2+}\) levels observed during stimulation with the purinergic receptor activator ATP (Fig. 1C and D).

**Levels of CXCR4, CXCR7, CD24 and HIF2α mRNA in MDA-MB-231 and MDA-MB-468 breast cancer cells.** To explore the potential reasons for the lack of CXCL12-induced \([\text{Ca}^{2+}]_{\text{CYT}}\) in MDA-MB-468 basal A breast cancer cells, compared with the significant increases observed in more metastatic MDA-MB-231 basal B breast cancer cells, mRNA expression of the potential regulators of CXCL12 responses were measured. Levels of mRNA for the CXCL12 receptor CXCR4 were significantly increased in MDA-MB-231 cells compared with MDA-MB-468 cells \((P<0.05; \text{Fig. 2)}\). Similarly, levels of CXCR7, another receptor for CXCL12 (6), were significantly increased in MDA-MB-231 cells compared with MDA-MB-468 cells \((P<0.05; \text{Fig. 2)}\). CD24 is a negative regulator of CXCL12 responses in MDA-MB-231 cells (13) and in the present study, it was revealed that there were significantly higher levels of CD24 mRNA in MDA-MB-468 cells \((P<0.05; \text{Fig. 2)}\), which were not responsive to CXCL12 as assessed by increases in \([\text{Ca}^{2+}]_{\text{CYT}}\) (Fig. 1C), compared with MDA-MB-231 cells. Given that an association between HIF2α and CXCR4 expression has been identified (14), HIF2α levels were also assessed in the two cell lines in the present study; however, no significant difference was observed (Fig. 2).

**Assessment of CXCR4, CXCR7, CD24 and HIF2α during hypoxia- and EGF-induced EMT in MDA-MB-468 breast cancer cells.** MDA-MB-231 is a basal B cell line and exhibits mesenchymal features, including vimentin expression and a lack of E-cadherin expression (30). Given that CXCL12-mediated
calcium signalling may be influenced by CXCR4, CXCR7 and CD24 (7,13), and that their expression differed between the more epithelial MDA-MB-468 (basal A) and the more mesenchymal MDA-MB-231 (basal B) breast cancer cell lines, the effect of EMT induction on CXCR4, CXCR7, CD24 and HIF2α expression in MDA-MB-468 cells was assessed. In the present study EMT induction with two distinct inducers was assessed to define the changes associated with EMT rather than the stimuli. Our previous studies of EMT in EGF and hypoxia models in this cell line produced increases in levels of the mesenchymal markers N-cadherin, zinc finger protein SNAI1, zinc finger E-box binding homeobox 1, CD44, twist-related protein and vimentin, downregulation of the epithelial markers E-cadherin and Claudin-4, as well as CD24, and changes to a more spindle morphology (31-33). In the present study, EGF and hypoxia produced opposing effects on CXCR4 levels and did not affect CXCR7 levels (Fig. 3A and B). Only the mRNA level of the known EMT marker CD24 was significantly decreased following induction of the EMT by the two inducers (P<0.01; Fig. 3C). HIF2α mRNA levels significantly increased following hypoxia (P<0.05), however they were unaffected by EGF (Fig. 3D).

**CXCR4 and CXCR7 expression is enriched in breast tumours with mesenchymal features.** Assessment of gene expression profiles in breast tumours classified based on the differential expression of 50 genes (PAM50) (29), demonstrated that CXCR4 and CXCR7 levels were higher in the C-Low subtype compared with the other subtypes (Fig. 4). The C-Low subtype is markedly associated with the EMT and stem cell-like features (34).

**Discussion**

The present study identified distinct CXCL12-induced Ca²⁺ responses between two basal-like breast cancer cell lines, MDA-MB-231 (basal B) and MDA-MB-468 (basal A). CXCL12-mediated Ca²⁺ responses were observed in MDA-MB-231 cells but not in MDA-MB-468 cells. It has been demonstrated that CXCL12/CXCR4-mediated Ca²⁺ signalling is enhanced in invasive breast cancer cell lines, such as MDA-MB-231 and BT-549, compared with non-metastatic cell lines, due to differences at the level of G protein subunit coupling that may prevent the activation of CXCR4 in less metastatic cell lines (35). The results of the present study expand upon these findings, as it was demonstrated that CXCL12-induced increases in [Ca²⁺]CYT were more pronounced in the more metastatic MDA-MB-231 cell line compared with less metastatic MDA-MB-468 cells.

The potential cause of differential CXCL12-induced Ca²⁺ signalling between MDA-MB-231 and MDA-MB-468 cells was explored by assessing the expression of the CXCL12 receptors CXCR4 and CXCR7, as well as potential regulators of CXCL12 responses, specifically CD24 and HIF2α (13,14). The results of the present study demonstrate that the expression of CXCR4 and CXCR7 is increased in MDA-MB-231 cells compared with MDA-MB-468 cells. The presence of CXCR4 and CXCR7 in the two breast cancer cell lines supports the results of previous studies which state that CXCR4 and CXCR7 are expressed in a variety of human malignancies, including in breast and lung cancer (36,37). The expression of CXCR4 and CXCR7 suggests that these receptors may contribute to the CXCL12-induced Ca²⁺ responses in MDA-MB-231 cells, which were observed in the present study. The non-responsiveness of MDA-MB-468 cells to CXCL12 stimulation (as measured by increases in Ca²⁺ levels) may be due in part to the decreased expression of CXCR4 and CXCR7 in this cell line compared with MDA-MB-231 cells. Analysis of CD24 mRNA expression indicated that CD24 was abundantly expressed in non-responsive MDA-MB-468 cells.
compared with MDA-MB-231 cells, a known feature of basal A cell lines compared with basal B (38). The differential CD24 expression detected in the present study is also consistent with the results of a previous study by Schindelmann et al (39); although this study did not assess MDA-MB-468 cells, it was reported that CD24 mRNA levels are generally increased in non-invasive breast cancer cell lines compared with invasive cell lines. The significant upregulation of CD24 observed in MDA-MB-468 cells may have also contributed to the attenuation of CXCL12-mediated Ca$^{2+}$ signalling in this cell line, given that CD24 interferes with CXCL12/CXCR4-mediated cell migration and tumour growth in pre-B lymphocytes and breast cancer cells (13). By contrast, levels of HIF2α, which has been demonstrated to modulate CXCR4 expression (14), did not differ significantly between the two cell lines, therefore it is unlikely to have contributed to any differences in CXCL12-mediated Ca$^{2+}$ signalling.

Having revealed that CXCR4, CXCR7 and CD24 were differentially expressed in more mesenchymal MDA-MB-231 cells (40) compared with MDA-MB-468 cells in their more epithelial state (17), the expression of these targets were investigated in MDA-MB-468 cells following EGF- and hypoxia-induced EMT. Induction of EMT with EGF in MDA-MB-468 cells decreased CXCR4 mRNA levels while the hypoxia-induced EMT was associated with a significant increase in CXCR4 levels. This suggests that the induction of the EMT via EGF and hypoxia differentially affects CXCR4 expression in MDA-MB-468 cells. Bertran et al (41) previously demonstrated an increase in CXCR4 expression in rat hepatoma cells treated with transforming proliferation factor-β to induce the EMT. Hence, transcriptional regulation of CXCR4 may differ depending on the EMT stimuli and may not be a fundamental characteristic of a more mesenchymal state. In the present study, CXCR7 levels were unaltered during hypoxia- and EGF-induced EMT in MDA-MB-468 cells. Hypoxia- and EGF-induced EMT in MDA-MB-468 cells produced a significant decrease in levels of CD24, consistent with its known association as a marker of the more epithelial state (31). CXCR4 and CXCR7 levels were enriched in the C-Low molecular subtype of breast tumours compared with the basal molecular subtype. The C-Low subtype is highly associated with metastastic, EMT and stem cell-like features (34,42). Hence, increased levels of CXCR4 and CXCR7 in C-Low sub-types of breast cancer is consistent with the increased levels of these two receptors in the basal B MDA-MB-231 breast cancer cell line, which usually exhibits increased levels of mesenchymal markers (30) compared with the less mesenchymal basal A MDA-MB-468 cell line (30). Hence, significant differences in CXCL12-induced Ca$^{2+}$ signalling may also be a feature of different types of breast cancer and influence their invasive/metastatic properties. This should be the primary focus of future in vivo studies as methods of assessing Ca$^{2+}$ signalling in xenografts continue to progress. In conclusion, these studies have defined distinct differences in CXCL12-mediated Ca$^{2+}$ signalling between MDA-MB-468 and MDA-MB-231 breast cancer cells. The present study also provides evidence for the occasional differential remodelling of potential Ca$^{2+}$ signalling regulators as a consequence of EGF and hypoxia in MDA-MB-468 breast cancer cells. It also provides evidence that CXCR4 and CXCR7 expression is enriched in breast tumours with mesenchymal features.

**Acknowledgements**

The present study was supported by the Ministry of Higher Education Malaysia Scholarship, a National Collaborative Research Program of the National Breast Cancer Foundation, Australia (grant no. GC-10-04), the National Health and Medical Research Council (grant no. 1022263), Queensland Cancer Council (grant no. 104281), Mater Research and the Australian Government.

**References**

1. Rossi D and Zlotnik A: The biology of chemokines and their receptors. Annu Rev Immunol 18: 217-242, 2000.
2. Perissinotto E, Cavalloni G, Leone F, Fonsato V, Mitola S, Grignani G, Surrenni N, Sangiolo D, Bussolino F, Picciello W and Aglietta M: Involvement of chemokine receptor 4/stromal cell-derived factor-1 system during osteosarcoma tumor progression. Clin Cancer Res 11: 490-497, 2005.
3. Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz IP and Ben-Baruch A: A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 167: 4747-4757, 2001.
4. Mochizuki H, Matsubara A, Teishima J, Mutaguchi K, Yasumoto H, Dahiya R, Usui T and Kamiya K: Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: A possible predictor of metastasis. Biochem Biophys Res Commun 320: 656-663, 2004.
5. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56, 2001.
6. Baldabian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, Arefanusa-Seisedes F, Thelen M and Bacherleir F: The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 280: 35760-35766, 2005.
7. Teicher BA and Fricker SP: CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16: 2927-2931, 2010.
8. Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taiichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 29: 709-722, 2010.
9. Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel RE and Jiang WG: Stromal cell derived factor-1: Its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 7: R402-R410, 2005.
10. Mukherjee D and Zhao J: The role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res 3: 46-57, 2013.
11. Xu C, Zhao H, Chen H and Yao Q: CXCR4 in breast cancer: Oncogenic role and therapeutic targeting. Drug Des Dev Ther 9: 4953-4964, 2015.
12. Kay R, Rosten PM and Humphries RK: CD24, a signal transducer modulating B cell activation responses, is a very short peptide with a glycosyl phosphatidylinositol membrane anchor. J Immunol 147: 1412-1416, 1991.
13. Schabath H, Runz S, Joumaa S and Altevogt P: CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 119: 514-325, 2006.
14. Imtiaz HZ, Williams EP, Hickey MM, Patel SA, Durham AC, Yuan LJ, Hammond R, Gimotty PA, Keith B and Simon MC: Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest 120: 2699-2714, 2010.
15. Pevarsky N, Skryma R and Shuba Y: Calcium in tumour metastasis: New roles for known actors. Nat Rev Cancer 11: 609-618, 2011.
16. Azimi I, Roberts-Thomson SJ and Monteith GR: Calcium influx pathways in breast cancer: Opportunities for pharmacological intervention. Br J Pharmacol 171: 945-960, 2014.

17. Davis FM, Kenny PA, Soo ET, van Deenderen BJ, Thompson EW, Cabot PJ, Parat MO, Roberts-Thomson SJ and Monteith GR: Remodeling of purinergic receptor-mediated Ca2+ signaling as a consequence of EGF-induced epithelial-mesenchymal transition in breast cancer cells. PLoS One 6: e23464, 2011.

18. Azimi I and Monteith GR: Plasma membrane ion channels and epithelial to mesenchymal transition in cancer cells. Endocr Relat Cancer 23: R517-R525, 2016.

19. McAndrew D, Grice DM, Peters AA, Davis FM, Stewart T, Rice M, Smart CE, Brown MA, Kenny PA, Roberts-Thomson SJ and Monteith GR: Orai1-mediated calcium influx in lactation and in breast cancer. Mol Cancer Ther 10: 448-460, 2011.

20. Motiani RK, Abdullaev IF and Trebak M: A novel native store-operated calcium channel encoded by Orai3: Selective requirement of Orai3 versus Orai1 in estrogen receptor-positive versus estrogen receptor-negative breast cancer cells. J Biol Chem 285: 19173-19183, 2010.

21. Peters AA, Simpson PT, Bassett JJ, Lee JM, Da Silva L, Reid LE, Song S, Parat MO, Lakhani SR, Kenny PA, et al: Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer. Mol Cancer Ther 11: 2158-2168, 2012.

22. Badwe S, Dabbas DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, et al: Basal-like and triple-negative breast cancers: A critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24: 157-167, 2011.

23. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527, 2006.

24. Aung CS, Ye W, Plowman G, Peters AA, Monteith GR and Roberts-Thomson SJ: Plasma membrane calcium ATPase 4 and the remodeling of calcium homeostasis in human colon cancer cells. Carcinogenesis 30: 1962-1969, 2009.

25. Stewart TA, Azimi I, Brooks AJ, Thompson EW, Roberts-Thomson SJ and Monteith GR: Janus kinases and Src family kinases in the regulation of EGF-induced vimentin expression in MDA-MB-468 breast cancer cells. Int JBiochem Cell Biol 76: 64-74, 2016.

26. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

27. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cancer genomics portal: An open platform for exploring multi-dimensional cancer genomics data. Cancer Discov 2: 401-404, 2012.

28. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomes and clinical profiles using the cBioPortal. Sci Signal 6: pl1, 2013.

29. Pereira B, Chin SF, Rueda OM, Vollan HJ, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, et al: Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic. Nat Commun 7: 11908, 2016.

30. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adélaïde J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D and Bertucci F: Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25: 2273-2284, 2006.

31. Davis FM, Azimi I, Faville RA, Peters AA, Jalink K, Putney JW Jr, Goodhill GJ, Thompson EW, Roberts-Thomson SJ and Monteith GR: Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent. Oncogene 33: 2307-2316, 2014.

32. Azimi I, Beilby H, Davis FM, Marcial DL, Kenny PA, Thompson EW, Roberts-Thomson SJ and Monteith GR: Altered purinergic receptor-Ca2+ signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells. Mol Oncol 10: 166-178, 2016.

33. Azimi I, Milevsky MJG, Kaemmerer E, Turner D, Yapa KTD, Brown MA, Thompson EW, Roberts-Thomson SJ and Monteith GR: TRPC1 is a differential regulator of hypoxia-mediated events and Akt signalling in PTEN-deficient breast cancer cells. J Cell Sci 130: 2292-2305, 2017.

34. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, et al: Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69: 4161-4124, 2009.

35. Holland JD, Kochetkova M, Akekwawatchai C, Dottore M, Lopez A and McColl SR: Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer cells. Cancer Res 66: 4177-4124, 2006.

36. Miao Z, Luker KE, Summers BC, Beralovich R, Bhojani MS, Rehemtulla A, Kleer CG, Essner J, Nasevic A, Luker GD, et al: CXCR7(RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci USA 104: 15735-15740, 2007.

37. Salvucci O, Bouchard A, Baccarelli A, Deschênes J, Sauter G, Simon R, Bianchi R and Basik M: The role of CXCR4 receptor expression in breast cancer. A large tissue microarray study. Breast Cancer Res Treat 97: 275-283, 2006.

38. Blick T, Hugo H, Widodo E, Pinto C, Mani SA, Weinberg RA, Neve RM, Lenburg ME and Thompson EW: Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi)/CD24(lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 15: 235-252, 2010.

39. Schindelmann S, Windisch J, Grundmann R, Kreienberg R, Davis FM, Azimi I, Faville RA, Simon R, Bianchi R and Basik M: Expression of CD24 in breast cancer cells. Mol Cancer Ther 11: 2162-2168, 2012.

40. Bertran E, Caja L, Navarro E, Berahovich R, Bhojani MS, Agarwal R, Joy C, et al: Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69: 4161-4124, 2009.

41. Prat A, Parker JS, Karginova O, et al: A collection of breast cancer cell lines: Correlation of in vitro invasiveness with expression of CD24. Tumor Biol 23: 139-145, 2002.

42. Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, et al: Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69: 4161-4124, 2009.

43. Slotin C, Slotin A, Patin E, et al: A collection of breast cancer cell lines: Correlation of in vitro invasiveness with expression of CD24. Tumor Biol 23: 139-145, 2002.
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Jamaludin, SYN; Azimi, I; Davis, FM; Peters, AA; Gonda, TJ; Thompson, EW; Roberts-Thomson, SJ; Monteith, GR

Title:
Assessment of CXC ligand 12-mediated calcium signalling and its regulators in basal-like breast cancer cells

Date:
2018-04-01

Citation:
Jamaludin, S. Y. N., Azimi, I., Davis, F. M., Peters, A. A., Gonda, T. J., Thompson, E. W., Roberts-Thomson, S. J. & Monteith, G. R. (2018). Assessment of CXC ligand 12-mediated calcium signalling and its regulators in basal-like breast cancer cells. ONCOLOGY LETTERS, 15 (4), pp.4289-4295. https://doi.org/10.3892/ol.2018.7827.

Persistent Link:
http://hdl.handle.net/11343/253447

File Description:
Published version

License:
CC BY-NC-ND